MACCE After Endoscopic Vein Harvest for CABG
Launched by THE ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST · Jun 10, 2015
Trial Information
Current as of May 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patient underwent CABG (isolated or combined) during period Jan 2012 to Dec 2013
- • 2. LSV harvested by EVH (Study group)
- • 3. LSV Harvested by OVH matched with EVH group (Control group)
- Exclusion Criteria:
- • 1. Patient deceased at time of study start
About The Royal Wolverhampton Hospitals Nhs Trust
The Royal Wolverhampton Hospitals NHS Trust is a leading healthcare provider in the West Midlands, dedicated to delivering high-quality patient care and advancing medical research through clinical trials. As a prominent NHS trust, it encompasses a range of specialized services across multiple hospitals, focusing on innovation and evidence-based practices. The Trust actively engages in clinical research to enhance treatment options and improve patient outcomes, fostering collaboration among healthcare professionals, researchers, and academic institutions. Committed to patient safety and ethical standards, the Royal Wolverhampton Hospitals NHS Trust plays a pivotal role in advancing healthcare through rigorous clinical trials and research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wolverhampton, , United Kingdom
Patients applied
Trial Officials
Heyman Luckraz
Principal Investigator
The Royal Wolverhampton NHS Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials